Sorrento Therapeutics Stock News

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for th

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of the SAD portion of the Phase 1 study of its oral main viral pro

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.

Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. Th

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhi

Sorrento's outsized ambitions are not playing well for shareholders. Sorrento has assembled a significant group of COVID-19 assets that could perk up its value as the pandemic smolders ever hotter.

Healthcare has become a bona fide stock picker's market this year.

Healthcare has become a bona fide stock picker's market this year.

PALO ALTO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “S

Are these penny stocks worth buying right now? The post Hot Penny Stocks to Buy This Week? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.